ArticleCureus2025
Evaluating the Efficacy of Ropivacaine Instillation Through a Subgaleal Drain for Postcraniotomy Pain: A Randomized Controlled Trial.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe majority of patients experience moderate to severe postcraniotomy pain, which causes several complications such as raised intracranial pressure, cerebral hemorrhage, chronic headache, etc. Therefore, this study aimed to assess the efficacy of ropivacaine instillation through subgaleal drain in patients undergoing elective craniotomy to reduce postcraniotomy pain. The primary objective of this study was to assess postoperative pain after craniotomy using the Numeric Rating Scale (NRS) score. MATERIALS AND
methodsA prospective, double-blinded, randomized controlled study was conducted in 120 patients posted for elective craniotomy, randomly allocated into three groups. Group A (n = 40) received 12 mL of 0.9% normal saline, Group B (n = 40) received 12 mL of 0.1% ropivacaine, and Group C (n = 40) received 12 mL of 0.2% ropivacaine. Postoperative NRS score, duration of analgesia, amount of rescue analgesia, patient satisfaction score, and hemodynamic parameters were compared in 24 hours among the three groups.
resultsThe NRS score was lowest in Group C compared to Group A and Group B at all time points, with significant differences observed at 30 minutes, 45 minutes, one hour, and two hours after drug instillation. The duration of analgesia was significantly prolonged in Group C (489.24 ± 204.5 minutes) compared to Group B (112.7 ± 156.5 minutes) and shortest in Group A (43.87 ± 24.2 minutes). The amount of rescue analgesic required was least in the 0.2% ropivacaine group (103.12 ± 36.3 mg) compared to the 0.1% ropivacaine group (144.37 ± 48.5 mg). It was in a substantial amount in the 0.9% normal saline group (176.2 ± 61.7 mg).
conclusionsWe concluded that for postcraniotomy pain, a single-dose 0.2% ropivacaine drug installation at the end of surgery through a surgical (subgaleal) drain had better pain control, a longer duration of analgesia, and a lower analgesic requirement compared to 0.1% ropivacaine and 0.9% normal saline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.